NARAYANA HRUDAYALAYA             
           | 
        |
| BOM : 539551     NSE : NH     | |
|    LT :                             
               
                
                
                                      
                                    
                
                
                    Long Term Analysis   
              
                
                
              
                     Fundamentals : Good 
                             
                  
              Valuation : Bad [Stock is Expensive] Debt : Average  | 
              Updated: | 
| ST :                              
                 
                  
                  
                  
                       Short Term Analysis   
                
                      
                    
          
                   
                       Quarterly Earnings Trend : Neutral 
                               
                    
                Price Momentum : Mild Upward Pledged Shares : None or < 25%  | 
                  Nov 03,2025 | 
| 
            Price(EOD): ₹ 1,785.70               
                  
                  
                  This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
                  
                    
            
             | 
            Hospital & Healthcare Services | 
| MCap: ₹ 36,499.71 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y | 
| NARAYANA HRUDAYALAYA | 0.6% | 3% | 42.3% | 
| MAX HEALTHCARE INSTITUTE | -2.8% | 3.1% | 15.3% | 
| APOLLO HOSPITALS ENTERPRISE | -0.7% | 5.1% | 10% | 
| FORTIS HEALTHCARE | -2.6% | 4.1% | 70.1% | 
| GLOBAL HEALTH | -5.9% | -2.3% | 22.8% | 
| KRISHNA INSTITUTE OF MEDICAL SCIENCES | 0.6% | 5.7% | 36.9% | 
| DR LAL PATHLABS | 5.3% | 2.7% | 2.6% | 
| ASTER DM HEALTHCARE | -3% | 7.6% | 57.4% | 
| RAINBOW CHILDRENS MEDICARE | -0.1% | 2.2% | -6.7% | 
FUNDAMENTAL ANALYSIS OF NARAYANA HRUDAYALAYA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NARAYANA HRUDAYALAYA
 | Ratio | Consolidated | |
|---|---|---|
| 
               P/E   P/B P/S  |  
                                
                46.51                   
                      
                      P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 784.58 Cr 
                [Latest Qtr - Jun2025 - Consolidated Results ] 10.06 
                      
                      P/B Calculated based on Book Value of Rs 3,626.20 Cr  
                [Latest Year - Mar2025 - Consolidated Results ] 6.35 
                      
                      P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 5,749.39 Cr  
                [Latest Qtr - Jun2025 - Consolidated Results ]  | 
              |
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+)  | 
          
|---|---|
| 
          EV/EBIDTA EV/Sales Price/Sales  | 
          
          43%  76% 70%  | 
          
SHARE PRICE MOMENTUM OF NARAYANA HRUDAYALAYA
NARAYANA HRUDAYALAYA vs SENSEX
DEBT OF NARAYANA HRUDAYALAYA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
| 
                        2025 2024 2023 Avg_3yrs  | 
                        
                        0.68  0.5 0.37 0.52  | 
                        
                  
                  
                  0.61  0.5 0.36 0.49  | 
                  
| 
                          [Last Annual Data : Mar2025]    
                       | 
                  ||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF NARAYANA HRUDAYALAYA
| Pledged Promoter Shares  | 
          
            
          
          0 % | |
|---|---|---|
| As on : Sep2025 | ||
If less than 25%  |    Good  | 
      
          |
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF NARAYANA HRUDAYALAYA
| Consolidated | Q-o-Q | Y-o-Y | 
|---|---|---|
| 
          Revenue Op Profit Profit Before Tax Profit After Tax  | 
          
           2.16% -5.81% -8.59% 0.13%  | 
          
           15.39% 11.41% 0.33% -2.07%  | 
|  QtrlyTrend | 
            2 | |
| Latest Qtr: Jun2025 | ||
| Quarterly Result Analysis → | ||
NARAYANA HRUDAYALAYA related INDICES
| BSE Indices | 1W | 1M | 1Y | 
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% | 
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% | 
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% | 
| BSE SMALLCAP | 0.9% | 4% | 2.5% | 
| BSE 250 SMALLCAP INDEX | 0.7% | 4.2% | 0.5% | 
| NSE Indices | 1W | 1M | 1Y | 
|---|---|---|---|
| NIFTY MIDSMALL HEALTHCARE | 1.6% | 3.6% | 6.8% | 
| NIFTY500 MULTICAP INFRASTRUCTURE 50:30:20 | 0.8% | 6.2% | 6.7% | 
| NIFTY SMALLCAP 50 | 0.7% | 6.4% | 2.4% | 
| NIFTY MIDSMALLCAP 400 | 0.7% | 5.2% | 5.3% | 
| NIFTY 500 EQUAL WEIGHT | 0.6% | 4% | 4.6% | 
You may also like the below Video Courses
FAQ about NARAYANA HRUDAYALAYA
Is NARAYANA HRUDAYALAYA good for long term investment?
As on Nov 03,2025, the Fundamentals of NARAYANA HRUDAYALAYA look Strong and hence it may be good for long term investment! See Financial Performance of NARAYANA HRUDAYALAYA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NARAYANA HRUDAYALAYA UnderValued or OverValued?
As on Nov 03,2025, NARAYANA HRUDAYALAYA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NARAYANA HRUDAYALAYA ?
As on Nov 03,2025, the Intrinsic Value of NARAYANA HRUDAYALAYA is Rs. 1,047.83 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,253.07
Fair Value [Median EV / Sales Model] : Rs. 1,014.69
Fair Value [Median Price / Sales Model] : Rs. 1,047.83
Estimated Median Fair Value of NARAYANA HRUDAYALAYA : Rs. 1,047.83
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.